Clinical Trial Search

Primary: % Patients Achieving Target Hemoglobin Levels — 42.5; 35.3 percentage of participants

Primary: Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to…

Primary: Change in Hemoglobin (Hgb) — 0.6; 0.2 g/dL

Primary: Hemoglobin Concentration at 6 Months — 117; 113 g/L

Primary: Mean Change From Baseline in Hemoglobin (Hgb) on Day 29 — 9.91; 0.63 Grams per decilitre (g/dL) — p=0.0020

Primary: Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period: Non-inferiority Analysis…

Primary: Percentage of Fractional Oral Iron Absorption Following Treatment With Daprodustat and rhEPO — 20.64; 20.62 Percentage (%) of iron absorbed — p=0.9971

Primary: Percentage of Participants by ESA Types at Baseline — 51.5; 17.3; 10.7; 20.4 percentage of participants

Primary: Percentage of Participants Who Experienced Increase and Maintain Hemoglobin Levels (Two Consecutive Values) Greater Than or Equal to the Lower Limit of the Target Range…

Primary: Change in Hb Concentration From Baseline to Week 16 — 0.50; -0.02 g/dl — p=0.0149

Primary: Baseline Hemoglobin Concentration — 10.3; 10.4 g/dL

Primary: Mean Change From Baseline in Hemoglobin (Hgb) During Evaluation Period (Week 28 to Week 52) — 1.02; 1.12 Grams per deciliter

Primary: Incidence of Treatment-emergent Serious Adverse Events (SAE's) — 11; 36 participants

Primary: Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis)…

Primary: Absolute Change From Baseline in Hemoglobin (Hgb) to End of Treatment (Week 6) — 9.46; 9.93; 9.86; 9.67 Grams per deciliter (g/dL) — p=<0.0001

Primary: Percentage of Participants With Hemoglobin (Hb) Response — 94.12; 93.51 percentage of participants — p=<0.0001

Primary: Mean Height of Participants at Baseline (Week 0) — 163.15 cm

Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 10.02; 10.03; 10.03; 11.55 g/dL

Primary: Change in Hemoglobin (Hb) Concentration From Baseline to Week 4. — 0.57; 0.35 g/dL

Primary: Percentage of Participants Achieving a Successful Hemoglobin Response — 54.9; 10.3 Percentage of participants — p==0.0001

Primary: Difference From Baseline to Day 15 in Area Under Curve (AUC) of GI Iron Absorption (0-3 Hours) — 11.288; -0.259; 20.125; -1.625 gram*3hours/deciliter (g*3hr/dL) — p=0.212

Primary: Percentage of Participants With Both Hemoglobin Values of the Evaluation Phase in the Range of 11-12 Grams Per Deciliter (g/dL) — 10.67 percentage of participants

Primary: Kaplan-Meier Survival Analysis for Time to Other Anemia Therapy or Hb Trigger — 36; 49; 98; 117 participants — p=0.026

Primary: Mean Change in Hemoglobin Between Baseline and the Evaluation Period — 10.05; 9.95; 10.05; 11.47 g/dL

Primary: Change in Hemoglobin From Baseline to the End of 8-week Treatment Period — 10.8; 11.1 g/dL

Primary: Change in Serum Hepcidin With Vitamin D Intervention for Children With Chronic Kidney Disease — 48.2; 75.4 ng/ml

Primary: Number (%) of Participants With an Hb Response by Week 17 — 19; 24; 21; 23 Participants

Primary: Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL — 87; 35 participants

Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 1; 0 Participants

Primary: Change in Ferritin From Baseline to End of Treatment — 60; 30 percentage of change from baseline